Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of "Hold" from Brokerages

Key Points

• Invivyd has a consensus “Hold” rating from six analysts: one sell, two hold, and three buy ratings. The average 12-month price target is $8.00, compared with the stock’s recent price of $1.02.
• The company reported a quarterly loss of $0.14 per share, missing the $0.11 consensus estimate, while revenue of $14.29 million was slightly below expectations. Analysts project a full-year loss of $0.51 per share.
• Insiders sold 228,024 shares worth approximately $176,540 during the last quarter, while institutional investors and hedge funds own 70.36% of the stock.

Shares of Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.00.

A number of equities research analysts have recently weighed in on IVVD shares. BTIG Research reaffirmed a "buy" rating on shares of Invivyd in a research note on Monday, September 14th. HC Wainwright reissued a "buy" rating on shares of Invivyd in a research note on Tuesday, August 18th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Invivyd in a research report on Thursday, August 27th. Finally, Weiss Ratings upgraded shares of Invivyd from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, September 8th.

Invivyd Trading Up 35.0%

NASDAQ IVVD opened at $1.02 on Tuesday. Invivyd has a 1-year low of $0.53 and a 1-year high of $3.07. The company has a market capitalization of $300.66 million, a PE ratio of -3.09 and a beta of 0.81. The firm's fifty day simple moving average is $0.77 and its 200-day simple moving average is $1.10.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The firm had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. As a group, analysts predict that Invivyd will post -0.51 EPS for the current year.

Insider Buying and Selling at Invivyd

In other news, insider Jill Andersen sold 37,256 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total transaction of $26,824.32. Following the transaction, the insider owned 314,480 shares in the company, valued at approximately $226,425.60. This trade represents a 10.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 228,024 shares of company stock worth $176,540. 12.25% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Invivyd

Hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new stake in shares of Invivyd in the fourth quarter worth about $53,809,000. BVF Inc. IL bought a new position in shares of Invivyd in the 4th quarter valued at approximately $48,227,000. Janus Henderson Group PLC raised its stake in shares of Invivyd by 1.7% in the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company's stock valued at $42,857,000 after acquiring an additional 551,188 shares in the last quarter. Jupiter Topco LLC acquired a new stake in Invivyd in the 2nd quarter worth approximately $30,048,000. Finally, Eventide Asset Management LLC acquired a new stake in Invivyd in the 4th quarter worth approximately $14,349,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc is a biotechnology company focused on developing antibody-based medicines designed to protect against rapidly evolving viral diseases. The company uses its antibody discovery and engineering platform to create therapies intended to maintain activity as viruses mutate and to provide durable protection for people who may not be adequately protected by vaccines.

Invivyd's lead product is pemivibart, marketed in the United States as Pemgarda. Pemivibart is an intravenously administered monoclonal antibody authorized by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.